EUVIMEDEUVIMED entdecken
Crossref

A Novel Immunohistochemistry Classifier for Ampullary Carcinoma: Highlighting the Prognostic Power of CDX2

Raiza Philip iD, M J Aparna iD, Rijo Issac iD, Shailaja Balakumar iD, Thomas Alex Kodiatte iD

Journal of Hepato-Biliary-Pancreatic Sciences · 2025

DOI: 10.1002/jhbp.70021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2025. Verfasst von Raiza Philip und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Pathology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: CDX2 Transcription Factor, Ampulla of Vater, Common Bile Duct Neoplasms. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ampullary carcinomas (AC) pose a diagnostic challenge while delineating into their prognostically distinct subtypes, pancreaticobiliary (PB) and intestinal (INT). This study aimed to correlate AC's histomorphological (HE) subtypes with its immunohistochemical (IHC) subtypes and evaluate their prognostic outcome.

Methods

This study was conducted in the Department of Pathology at a tertiary care cancer hospital. One hundred cases of ACs in pancreatoduodenectomy specimens were selected. Slides were reviewed for HE subtyping of ACs, including Intra‐Ampullary papillary‐tubular Neoplasms into HE‐PB and HE‐INT subtypes. IHCs (MUC1, MUC2, MUC5AC, CDX2 and CK20) were performed. ACs were classified into IHC‐PB or IHC‐INT types using various IHC schemata. IHC and HE subtypes were correlated using Pearson's Chi‐square test. Sensitivity, specificity, positive predictive values, and negative predictive values were calculated for the IHCs. Survival status was analyzed using the Kaplan–Meier survival analysis. Results and Conclusion The PB subtype showed a higher pathological tumor stage than INT. Among the various schemas evaluated, the Harthimmer Integrated Liu Layered Scoring system performed best with a significant correlation between HE and IHC subtypes. INT subtypes had better prognostic outcomes than PB subtypes. We found an essential prognostic role of CDX2 in the stratification of ACs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CDX2 Transcription FactorAmpulla of VaterCommon Bile Duct NeoplasmsHumansMalePrognosisFemaleImmunohistochemistryMiddle AgedAgedRetrospective StudiesBiomarkers, TumorPancreaticoduodenectomyAged, 80 and overAdultNeoplasm StagingKaplan-Meier Estimate

Stichwörter der Autor:innen

ampullary carcinomaintestinalpancreaticobiliary

Substanzen

CDX2 Transcription FactorCDX2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of General Pathology, Christian Medical College, Vellore, India.
  • Department of Hepato Pancreato-Biliary Surgery, Christian Medical College, Vellore, India.

ORCID-Profile: Raiza Philip, M J Aparna, Rijo Issac, Shailaja Balakumar, Thomas Alex Kodiatte

Zitieren

APA

Philip, R., Aparna, M. J., Issac, R., Balakumar, S., & Kodiatte, T. A. (2025). A Novel Immunohistochemistry Classifier for Ampullary Carcinoma: Highlighting the Prognostic Power of CDX2. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70021

Vancouver

Philip R, Aparna MJ, Issac R, Balakumar S, Kodiatte TA. A Novel Immunohistochemistry Classifier for Ampullary Carcinoma: Highlighting the Prognostic Power of CDX2. Journal of Hepato-Biliary-Pancreatic Sciences. 2025. doi:10.1002/jhbp.70021

BibTeX
@article{Philip2025,
  author = {Philip, Raiza and Aparna, M J and Issac, Rijo and Balakumar, Shailaja and Kodiatte, Thomas Alex},
  title = {A Novel Immunohistochemistry Classifier for Ampullary Carcinoma: Highlighting the Prognostic Power of CDX2},
  journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
  year = {2025},
  doi = {10.1002/jhbp.70021}
}
Kostenlos starten →